nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

06.10.2022 | review

Dual checkpoint-blockade in urothelial carcinoma—when is it so far

verfasst von: Karl Mayrhofer, MD, Dora Niedersüß-Beke, MD, MBA

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Summary

Single agent immunotherapy is routinely used in the treatment of localised and advanced bladder cancer. Dual checkpoint inhibition with nivolumab (nivo)–ipilimumab (ipi) and durvalumab (durva)–tremelimumab (treme) shows encouraging activity in phase I/II trials in the neoadjuvant and metastatic disease setting. Several large trials are testing these combinations against the current standard of care. The so far reported results are negative; however, it appears that a subgroup of patients might profit substantially from dual checkpoint blockade. Ongoing trials will elucidate which patients will be candidates for this treatment modality in routine clinical care.

Vorheriger Artikel Essential news for clinical practice—thyroid cancer

Nächster Artikel Dual immune checkpoint blockade in gastroesophageal tumors: never say never

Grimm M‑O, Grün B, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, et al. Tailored immunotherapy approach with nivolumab in advanced transitional cell carcinoma (TITAN-TCC). J Clin Oncol. 2022;40(6_suppl):441–441.CrossRef

Sharma P, Siefker-Radtke AO, de Braud F, Basso U, Calvo E, Bono P, et al. Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): extended follow-up from CheckMate 032. Ann Oncol. 2020;31:S582–S3.CrossRef

Galsky MD, Powles T, Li S, Hennicken D, Sonpavde G. A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901). J Clin Oncol. 2018;36(6_suppl):TPS539–TPS539.CrossRef

Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1574–88.CrossRefPubMed

Galsky MD, Necchi A, Sridhar SS, Ogawa O, Angra N, Hois S, et al. A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE). J Clin Oncol. 2021;39(6_suppl):TPS504–TPS504.CrossRef

van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020;26(12):1839–44.CrossRefPubMed

Gao J, Siefker-Radtke AO, Navai N, Campbell MT, Slack Tidwell R, Guo C, et al. A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA‑4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC). J Clin Oncol. 2019;37(15_suppl):4551–4551.CrossRef

Grande E, Guerrero F, Puente J, Galante I, Duran I, Dominguez M, et al. DUTRENEO Trial. A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature. J Clin Oncol. 2020;38(15_suppl):5012–5012.CrossRef

Pfister C, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, et al. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial. J Clin Oncol. 2022;40(18):2013–22.CrossRefPubMed

10.

Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102–14.CrossRefPubMedPubMedCentral

11.

Powles T, Drakaki A, Teoh JY‑C, Grande E, Fontes-Sousa M, Porta C, et al. A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA). J Clin Oncol. 2022;40(6_suppl):TPS579–TPS579.CrossRef

12.

Garcia del Muro X, Valderrama BP, Medina A, Cuellar MA, Etxaniz O, Gironés Sarrió R, et al. Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: Immunopreserve-Sogug trial. J Clin Oncol. 2021;39(15_suppl):4505–4505.CrossRef

Titel: Dual checkpoint-blockade in urothelial carcinoma—when is it so far
verfasst von: Karl Mayrhofer, MD
Dora Niedersüß-Beke, MD, MBA
Publikationsdatum: 06.10.2022
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-022-00839-0

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Update on systemic therapy for clear cell renal cell carcinoma

Surgical management of liver metastasis from colorectal cancer

Lymphomas off the beaten track

Best of hematology—2021

Colorectal cancer special, part 1

Radiotherapy update: current role of radiotherapy in the treatment of lymphomas